VJHemOnc is committed to improving our service to you

ASH 2019 | PET-CT findings have prognostic value in NDMM

VJHemOnc is committed to improving our service to you

Philippe Moreau

Philippe Moreau, MD, University Hospital Hôtel-Dieu, Nantes, France, discusses the results of the CASSIOPET study. This study evaluated the prognostic value of positron emission tomography-computed tomography (PET-CT) at diagnosis and follow-up in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients treated in the phase III CASSIOPEIA trial (NCT02541383). Results show that baseline PET-CT negativity is associated with a better outcome. Additionally, Prof. Moreau reveals that daratumumab improves the outcome of baseline PET-CT negative and positive patients. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter